2024 AACR Annual Meeting

The American Association for Cancer Research (AACR) Annual Meeting 2024 took place April 5-10 in San Diego, California.

The ELM-2 trial studied odronextamab in patients with relapsed or refractory follicular lymphoma.

Dr. Colla describes her current research at MD Anderson, such as developing new therapeutic approaches to MDS.

Dr. Bertoni and colleagues characterized two small nucleolar RNAs that exert tumor suppressor activity in DLBCL cells.

Catherine Coombs, MD, outlined some of her research into the solid tumor microenvironment, particularly in prostate cancer.

The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and ...

Dr Cliff describes an analysis of oncology drugs that were approved via the FDA Accelerated Approval Program over 10 years.

Dr. Cavalli was honored for his accomplishments in the fields of leukemia, lymphoma, and breast cancer.

Dr. Witte’s recent research focuses on finding immunological targets for both antibody and cell-mediated therapy.

Paolo Ghia, MD, PhD talks about his session on monoclonal B-cell lymphocytosis presented at the AACR Annual Meeting 2024.

Claudio Cerchione, MD, PhD, describes his presentation from AACR 2024 on a emavusertib triplet in patients with AML.

$Sundar Jagannath, MBBS, on Linvoseltamab in Relapsed or Refractory Myeloma$

The overall response rate was 71%, and the most common side effects were CRS, neutropenia, and anemia.